SCHEMBL4548394

SCHEMBL4548394

COC(=O)/C=C/c1cn2c(n1)sc1cc(OC)ccc12

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.54
TP53 P04637 4/20 0.54
LMNA P02545 2/20 0.54
TSHR P16473 1/20 0.54
RAB9A P51151 1/20 0.54
ATM Q13315 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
APP P05067 1/20 0.53
KDM4E B2RXH2 1/20 0.49
ALDH1A1 P00352 1/20 0.49
PARP15 Q460N3 1/20 0.48
PARP10 Q53GL7 1/20 0.48
TNKS2 Q9H2K2 1/20 0.48
PARP2 Q9UGN5 1/20 0.48
RXFP1 Q9HBX9 1/20 0.48
THRB P10828 2/20 0.44
FLT3 P36888 1/20 0.44
POLB P06746 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14349883 0.90 TP53 (0.58) MAPTTP53LMNATSHRRAB9A
SCHEMBL14349884 0.87 MAPT (0.52) MAPTTP53LMNATSHRRAB9A
SCHEMBL2930089 0.83 MAPT (0.60) MAPTTP53LMNATSHRRAB9A
SCHEMBL14349882 0.81 MAPT (0.48) MAPTTP53LMNATSHRRAB9A
SCHEMBL22371638 0.78 MAPT (0.49) MAPTTP53LMNATSHRRAB9A
SCHEMBL17129983 0.77 MAPT (0.69) MAPTTP53LMNATSHRRAB9A
Hydrochloric Acid SCHEMBL10465281 0.76 MAPT (0.67) MAPTTP53LMNATSHRRAB9A
SCHEMBL17620857 0.76 TP53 (0.64) MAPTTP53LMNATSHRRAB9A
SCHEMBL2930357 0.73 MAPT (0.60) MAPTTP53LMNATSHRRAB9A
SCHEMBL21276497 0.73 MAPT (0.60) MAPTTP53LMNATSHRRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME CORP. (US) 2012-07-12 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-8168649-B2 Niacin receptor agonists, compositions containing such compounds and methods of treatment Merk Sharp & Dohme Corp. (US) 2012-05-01 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment MERCK SHARP & DOHME LLC 2010-06-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144778-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, GPR119 MAPT 2721/4885TP53 3458/4885LMNA 851/4885
US-20120178750-A1 Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment HCAR1, HCAR2, FFAR1 MAPT 2701/4885TP53 3377/4885LMNA 909/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.